NEUMORA THERAPEUTICS, INC. Net Change in Cash
NEUMORA THERAPEUTICS, INC. (NMRA) reported Net Change in Cash of -$65.70 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-14
- NEUMORA THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$35.46M.
- NEUMORA THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$15.29M.
- NEUMORA THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$191.11M.
- NEUMORA THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$30.12M.
- NEUMORA THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $39.17M.
- NEUMORA THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$231.89M, a 274.29% decline from fiscal 2023.
- NEUMORA THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was $133.04M.
- NEUMORA THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$167.17M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$65.70M 10-Q · filed 2026-08-14 | |||
| 2026-03-31 | -$35.46M 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $39.17M 10-K · filed 2026-03-30 | |||
| 2025-09-30 | -$14.29M 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | -$18.84M 10-Q · filed 2026-08-14 | |||
| 2025-03-31 | -$15.29M 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | -$231.89M 10-K · filed 2026-03-30 | |||
| 2024-09-30 | -$98.32M 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | -$223.36M 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | -$191.11M 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $133.04M 10-K · filed 2025-03-03 | |||
| 2023-09-30 | $171.29M 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | -$36.77M 10-Q · filed 2024-08-06 | |||
| 2023-03-31 | -$30.12M 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | -$167.17M 10-K · filed 2025-03-03 | |||
| 2022-09-30 | -$155.60M 10-Q · filed 2023-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |